Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide

Bone Marrow Transplantation

Volumn 26, Issue 3, 2000, Pages 309-313

  Snowden, J A ^a   Hill, G R ^a   Hunt, P ^a   Carnoutsos, S ^a   Spearing, R L ^a   Espiner, E ^a   Hart, D N J ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b Mater Medical Research Institute   (Australia)

Author keywords

Bone marrow transplantation; Brain natriuretic peptide; Cardiac failure; Stem cell transplantation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; MESNA;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0033863029     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702507     Document Type: Article

References (34)

1. Petersen FB, Bearman SI. Preparative regimens and their toxicity. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994, pp 82-83.
2. Feneley MP, Lim CA. Cardiac complications. In: Atkinson K (ed). Clinical Bone Marrow and Stem Cell Transplantation. Cambridge University Press: Cambridge, 2000, pp 952-957.
3. Cazin B, Gorin NC, Laporte JP et al. Cardiac complications after bone marrow transplantation. A report on 63 consecutive transplantations. Cancer 1986; 57: 2061-2069.
4. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
5. Goldberg M, Antin JH, Guinin EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
6. Parillo JE. Cardiovascular dysfunction in septic shock: new insights into a deadly disease. Int J Cardiol 1985; 7: 314-321.
7. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmia, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91-98.
8. Sudoh T, Kangawa K, Minamino N et al. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
9. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991; 87: 1402-1412.
10. Lang RE, Tholken H, Ganten D et al. Atrial natriuretic factor - a circulating hormone stimulated by volume loading. Nature 1985; 314: 264-267.
11. Yasue H, Yoshimura M, Sumida H et al. Localisation and mechanism of secretion of B-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-200.
12. Choy AJ, Darber D, Lang C et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994; 72: 16-22.
13. Davidson NC, Naas AA, Hanson JK et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828-831.
14. Davis M, Espiner E, Richards G et al. Plasma BNP in assessment of acute dysnoea. Lancet 1994; 343: 440-443.
15. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in the assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1347-1351.
16. Blume K, Forman S, O'Donnell MR et al. Total body irradiation and high dose etoposide: a new preparatory regimen for bone marrow transplant in patients with advanced hematologic malignancies. Blood 1987; 69: 1015-1020.
17. Powles R, Milliken S, Helenglass G et al. The use of melphalan in conjunction with total body irradiation as treatment for acute leukaemia. Transplant Proc 1989; 21: 2955-2957.
18. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistent Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
19. Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Ann Intern Med 1986; 104: 163-168.
20. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplant for leukemia. New Engl J Med 1986; 314: 729-735.
21. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia. Blood 1989; 73: 1729-1734.
22. Sullivan K. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED. Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994, pp 339-362.
23. Yandle TG, Richards AM, Gilbert A et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76: 832-838.
24. Fleischer D, Espiner EA, Yandle TG et al. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea. NZ Med J 1996; 100: 71-74.
25. Richards AM, Crozier IG, Yandle TG et al. Brain natriuretic factor: regional plasma concentrations and correlations with haematodynamic state in cardiac disease. Br Heart J 1993; 69: 414-417.
26. Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac disease. Clin Endocrinol 1997; 47: 287-296.
27. Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic and adrenomedulin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-1929.
28. Haupt MT, Rackow ED. Adverse effects of febrile state on cardiac performance. Am Heart J 1983; 105: 763-768.
29. Richards AM, Nicholls MG, Yandle TG et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999; 81: 114-120.
30. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance. J Intern Med 1990; 227: 259-266.
31. Gardner SF, Lazarus HM, Bednarczyk EM et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 1993; 12: 139-144.
32. Buja LM, Ferrans VJ, Graw RG. Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum Pathol 1976; 7: 17-45.
33. Bauch M, Ester A, Kimura B et al. Atrial natriuretic peptide as a market for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69: 1492-1497.
34. Aisenburg AC. Problems in Hodgkin's disease management. Blood 1999; 93: 761-779.